Melanoma Coverage from Every Angle

FDA Approves Pembrolizumab in Adjuvant Treatment of Melanoma

By: Sarah Jackson
Posted: Wednesday, February 20, 2019

On February 19, 2019, the U.S. Food and Drug Administration (FDA) approved the anti–PD-1 therapy pembrolizumab (Keytruda) in the adjuvant treatment of patients with melanoma with involvement of lymph node(s) after complete resection.

Approval was based on the results from the EORTC1325/KEYNOTE-054 trial ( identifier NCT02362594). This phase III trial, which was conducted in collaboration with the European Organisation for Research and Treatment of Cancer, demonstrated that patients with resected, high-risk stage III melanoma who received pembrolizumab experienced fewer recurrences/deaths, 26% (n = 135), than those who received placebo, 43% (n = 216). Pembrolizumab is the first ant–-PD-1 therapy studied in the adjuvant setting across patients with stages IIIA, IIIB, and IIIC melanoma.

A total of 76% of patients received pembrolizumab for 6 months or longer. Pembrolizumab was discontinued for adverse reactions in 14% of patients. The most common adverse reactions were diarrhea, pruritus, nausea, arthralgia, hypothyroidism, cough, rash, asthenia, influenza-like illness, weight loss, and hyperthyroidism.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.